Stocktoria
CYTOKINETICS INC CYTK
CYTOKINETICS INC (CYTK) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $88.0M at a -891.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-10 | Truist Securities | Buy (main) |
| 2026-08-07 | RBC Capital | Outperform (main) |
| 2026-08-07 | Citizens | Market Outperform (main) |
| 2026-08-07 | Needham | Buy (main) |
| 2026-07-07 | RBC Capital | Outperform (main) |
| 2026-06-29 | UBS | Buy (up) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.502 |
| Retained earnings / assets | -2.448 |
| EBIT / assets | -0.43 |
| Equity / liabilities | -0.316 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CYTK | CYTOKINETICS INC | 3/9 | -7.91 | — | +376.6% |
| SPRY | ARS Pharmaceuticals, Inc. | 3/9 | -1.13 | — | -5.5% |
| NRIX | Nurix Therapeutics, Inc. | 3/9 | 1.2 | — | +54% |
| ARCT | Arcturus Therapeutics Holdings Inc. | 1/9 | 0.81 | — | -46.1% |
| SIGA | SIGA TECHNOLOGIES INC | 5/9 | 16.02 | 12.1 | -31.8% |
| ETON | Eton Pharmaceuticals, Inc. | 5/9 | -2.05 | — | +104.9% |
| CTMX | CytomX Therapeutics, Inc. | 1/9 | -10.12 | — | -44.8% |
About CYTOKINETICS INC
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
FAQ
Is CYTK financially healthy?
CYTOKINETICS INC's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CYTK pay a dividend?
No, CYTOKINETICS INC does not currently pay a dividend.
How profitable is CYTK?
In FY2025, CYTOKINETICS INC had a net margin of -891.6%.
What is the analyst price target for CYTK?
The average Wall-Street price target for CYTOKINETICS INC is $108.85, about 43.9% above the recent price, from 20 analysts (consensus: strong buy).
Is CYTK a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CYTOKINETICS INC: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.